Standard Zinc Dosing for Male Patients with Alcohol Use Disorder
For adult males with alcohol use disorder, the standard dose is 220 mg zinc sulfate orally daily, which provides 50 mg of elemental zinc 1.
Rationale and Evidence Base
The 2020 AASLD Practice Guidance on alcohol-associated liver diseases specifically recommends therapeutic doses of zinc in moderate and severe alcoholic hepatitis, noting that most patients with chronic alcohol abuse are zinc-deficient 2. This deficiency occurs early in the course of alcohol-associated liver disease and contributes to gut barrier dysfunction and hepatocyte injury 1.
Key Clinical Considerations
Zinc deficiency is nearly universal in AUD patients and plays a critical mechanistic role in disease progression through:
- Intestinal barrier dysfunction leading to increased gut permeability
- Enhanced inflammatory responses (particularly elevated IL-8 in zinc-deficient patients) 3
- Hepatocyte apoptosis and necrosis 3
- Impaired immune function 2
Dosing Details
The recommended formulation is:
- 220 mg zinc sulfate = 50 mg elemental zinc daily 1
This dose has been shown effective in:
- Correcting zinc deficiency in ALD patients
- Improving gut mucosal barrier integrity
- Preventing and treating experimental ALD 1
Duration and Monitoring
Historical data shows that:
- Serum zinc normalizes within 10 days to 2 months of supplementation 4
- Hepatic zinc concentrations improve but may remain below normal, particularly in cirrhotic patients, even after 60 days of supplementation 4
- No adverse reactions were observed with 600 mg zinc sulfate daily (approximately 135 mg elemental zinc) in older studies 4
Important Caveats
Sex differences matter: Female AUD patients with zinc deficiency show more severe gut-immune-liver axis dysfunction, with a shift from apoptotic to necrotic hepatocyte death patterns, suggesting more advanced subclinical disease 3. However, the dosing recommendation remains the same regardless of sex.
Timing of initiation: Because zinc deficiency occurs early in ALD progression 1, supplementation should be considered in most AUD patients, not just those with clinically apparent liver disease.
No FDA-approved therapy exists for any stage of ALD 1, making zinc supplementation one of the few evidence-based interventions with established safety and biological plausibility for disease modification.